XBiotech announced that it has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis, or AD. XBiotech has now completed and exceeded enrollment in the final cohort of patients who are receiving 400mg weekly doses of bermekimab over an 8 week treatment period. Enrollment for the study is now closed. XBiotech recently announced it completed the first cohort of patients in the study who received a low dose of bermekimab over a four week treatment regimen. The company reported that patients in the first cohort had significant improvement in multiple efficacy endpoints and that the treatment was well-tolerated.
Friday, October 5, 2018
Acorda target cut to $19 to account for Ampyra generics, Inbrija delay at Stifel
Stifel analyst Paul Matteis lowered his price target on Acorda Therapeutics shares to account for the arrival of Ampyra generics and the FDA’s extension of Inbrija’s PDUFA to early next year, which leads him to move his Inbrija launch expectation back by a quarter to the first quarter of 2019. The analyst, who cut his target to $19 from $25, keeps a Hold rating on Acorda shares.
https://thefly.com/landingPageNews.php?id=2800293
Abbott price target raised to $86 from $72 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $86 from $72 and said it remains a top pick. The analyst cited increased visibility from Libre and MitraClip reinforcing confidence in top tier revenue and earnings growth, which he sees supporting a peer average multiple. Jennings reiterated his Outperform rating on Abbott shares.
https://thefly.com/landingPageNews.php?id=2800317
Evolent Health resumed with an Outperform at Leerink
Leerink analyst David Larsen resumed coverage of Evolent Health with an Outperform rating and $35 price target, telling investors in a research note that he remains positive on shares following the close of the New Century Health acquisition. Larsen says he is “more confident” in Evolent’s growth prospects given the company’s greater presence in Medicare Advantage, Oncology and Cardiology, and says the deal makes strategic sense and will help enable Evolent to serve as a “conduit” between providers and payors to drive lower costs and improved outcomes.
https://thefly.com/landingPageNews.php?id=2800329
Thursday, October 4, 2018
ANI Launches Authorized Generic of Atacand HCT® Tablets
ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®. The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health.
Arthur S. Przybyl, ANI’s President and CEO stated, “We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT®. This launch represents ANI’s sixth generic new product introduction in 2018.”
About Atacand HCT® Tablets
Atacand HCT® is indicated for the treatment of hypertension.
ARYA Sciences Acquisition Corp. Prices $125 Million IPO
ARYA Sciences Acquisition Corp. (“ARYA” or the “Company”), announced today that it priced its initial public offering of 12,500,000 units at $10.00 per unit for aggregate gross proceeds of $125,000,000. The sponsor of ARYA is ARYA Sciences Holdings, which is controlled by principals of Perceptive Advisors, LLC. The Company has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 units to cover over-allotments, if any. The units are expected to begin trading on The Nasdaq Capital Market on October 5, 2018 under the symbol “ARYAU”. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
The offering is expected to close on October 10, 2018, subject to customary closing conditions.
Jefferies LLC is acting as the sole book-running manager and Chardan is acting as the lead manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 4, 2018. The offering will be made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ARYA
We are a newly organized blank check company newly incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with respect to identifying any business combination target.
Allscripts, Appriss Partner on Access to Prescription Med Monitoring, Abuse Data
Allscripts (NASDAQ:MDRX), a global leader in health care technology, today announced a nationwide integration partnership with Appriss Health, provider of the most comprehensive platform for substance use disorder (SUD) in the U.S., to enable point-of-care access directly to prescription drug monitoring program (PDMP) information and Appriss Health’s NarxCare platform via Allscripts ePrescribe, Allscripts Professional EHR™, Allscripts TouchWorks® EHR, Practice Fusion™ EHR and Allscripts Sunrise™ electronic health record (EHR) platforms. The integration, via Appriss Health’s PMP Gateway platform, of information, advanced analytics, tools, and resources into Allscripts’ platforms can help support clinical decision making, improve patient outcomes, and better ensure patient safety.
This partnership will accelerate access and increase utilization for prescribers across all Allscripts’ EHR platforms using Appriss Health’s NarxCare platform. Utilizing this new integration model, when providers sign up and update their EHR or ePrescribe version, the integration will be automatically established from the practice direct to Allscripts, which in turn sends, receives and delivers the data from NarxCare back to the provider in real-time.
“Our vision at Allscripts is to build open, interoperable connected communities of care,” said Tom Langan, CEO, of Payer & Life Sciences at Allscripts. “As the opioid crisis grows, changes and continues to devastate the U.S., we are aggressively moving to provide our clinicians with a solution that offers objective information and insights into a patient’s risk for drug misuse, abuse, overdose, and death, so patients can be provided with the most effective and appropriate care. This integration partnership with Appriss Health is one in a series of important steps we are taking to act on our mission to efficiently deliver the best solutions available to our providers to enable smarter care, with greater precision, for healthier patients and communities.”
Recently, the CDC predicted that more than 71,000 people in the U.S. died from drug overdose death in the 12-month period ending in January 2018.
Appriss Health’s PMP Gateway platform increases utilization of PDMP information, other information, resources and more, up front, for every patient, at every patient encounter. By delivering both PDMP information and NarxCare within the clinicians’ workflow in Allscripts, this one-click process eliminates the need for providers nationwide to manually log into each state PDMP website separately and then enter a patient’s name and demographics. This easy access to real-time information helps providers to better evaluate and intervene as appropriate with their patients.
All Allscripts ambulatory and acute EHR platforms feature electronic prescribing of medications, a central component of the clinical workflow process which both informs and automates the prescribing process in real-time for thousands of prescribers and millions of patients.
Subscribe to:
Posts (Atom)